SLC5A2 and female reproductive system neoplasm: Gynecologic tumors—which include malignancies of the uterus, cervix, endometrium, ovary, breast, vagina, and vulva—are prevalent among individuals who meet the indications for GLP-1 receptor agonists or SGLT2 inhibitors [14–16].